Question
click below
click below
Question
Normal Size Small Size show me how
Bipolar Pharma
Behavioral Medicine Pharmacology
Question | Answer |
---|---|
Bipolar: theories | monoamine,dysregulation, anticholinergic, kindling, neuroendocrine, membrane & cation hypothesis, secondary messenger system, biologic rhythms, switch phenomenon |
Lithium MOA | not well known; Block DA rec sensitivity; inc NE release in depn; dec NE release in mania; reduces beta-adrenergic stim of adenylate cyclase; inc 5-HT synth |
Lithium indicated for | acute mania; maintenance |
Lithium advantages | antidep & antimanic fx (no switching nec); prevent relapse; better than valproate at prevent suicide |
Lithium: best results in pts: | Fewer prior episodes; hx euthymia; Periods of good functioning; Pos FH w/Lithium |
Lithium: reduced fx: | severe mania w/psychotic; mixed episodes; rapid / continuous cycling; etoh/ drug abuse |
Lithium dosing | start at 600-900; inc by 300 q 2-3d (target 900-2400) |
Lithium Monitoring | Draw trough 12h post last dose (tx day 5); then 1-2 wks for 1st mos; 5 days post dose change |
Lithium tx serum level | 0.8 to 1.2 mEq/L (acute manic: poss 1.2 – 1.5); SR has no ref range |
Lithium half life | usu 24 h (8 – 20 h in mania) |
Lithium AE (early) | Blocks ADH fx on its receptors (polydipsia / polyuria); mx weakness; fine hand (intentional) tremor |
Lithium AE (late) | NDI; increased lytes (Na, K, H2O), Cr; cardiac; persistent neuro probs (memory loss; MG, EPS); thyroid; GI; inc WBC & wt |
Leading cause of lithium noncompliance | loss of creativity / memory |
Lithium toxicity factors | Na restriction; dehydration; drug interactions |
Lithium: mild toxicity = | 1.5 – 2.0; prob memory/conc; GI; tremor |
Lithium: moderate toxicity = | 2.0-2.5; confusion, ataxia, nystagmus, inc DTR |
Lithium: severe toxicity = | over 3.0; Choreoathetosis, seizure, coma, death |
Tx lithium tox (>2.5) | d/c lithium; gastric lavage; monitor levels |
Tx lithium tox (>3.5) | d/c d/c lithium; hemodialysis; monitor levels |
Lithium CI | Renal dz; severe CV dz; hx leukemia; first tri of PG; hypersensitivity; breastfeeding? |
Drugs that have anti-kindling properties | anticonvulsants (Valpro, carbamazepine, lamotrigine) |
Bipolar drugs: category D (avoid in PG, dc in first trimester): | lithium, valpro, carba |
Valpro MOA | Unk; prob inhib GABA metab &stim GABA synth |
Valpro good for: | FDA: acute mania, rapid cycling (> lithium at mixed, secondary bipolar, subst induced) |
Valpro less good for: | depression |
Valpro absorption delayed: | with food |
Valpro AE | GI, sedation, ataxia/tremor, low plt, liver probs |
Carbamazepine MOA | Unk; prob block voltage-sensitive Na+ channels; Block CA+ influx thru NMDA-glutamate receptor |
Carbamazepine efficacy | XR same as lithium; also acute mania, prophylaxis, bipolar depn |
Carbamazepine better than lithium: | Severe mania; Rapid cycling; Mixed episodes |
Carbamazepine dosing | start 200-400 mg/d; target 400-2400; max 15mg/kg/d |
Carbamazepine monitoring | no est tx level; anticonvulsant = 6-12 mcg/ml; carba levels 12h postdose & day 6 |
Carbamazepine PK | well absorbed (not affected by food); peak levels in 1-5 hr; 80% pro bound |
Carbamazepine AE | CNS tox; GI (divide doses); leukopenia, hepatotox, low plt; SIADH, osteomalacia, derm |
Carbamazepine potentially lethal: | >15 mcg/ml |
Carbamazepine CI | bone marrow depn; hypersensitivity |
Lamotrigine MOA | Blocks voltage-sensitive Na+ and Ca+ channels |
Lamotrigine efficacy | maintenance (esp bipolar depn); NOT for acute mania |
Lamotrigine PK | well absorbed (not affected by food); peak levels 1-4 hr; half life 25 hr (so x1/d dose) (inc to 60 hr w/valpro) |
Lamotrigine AE | usu well tolerated; Stevens Johnsons syndrome; rash |
antipsychotics dosing | Risperidone, olanzapine, quetiapine: mono or combo w/valp or lithium; aripiprazole, ziprasidone: monotx |
antipsychotics good for: | acute mania; mixed (Quetiapine: bipolar depn) |
SSRIs in bipolar depn | monotx inappropriate; high uncertainty in risk to manic switch |
Benzo: benefit in bipolar | Reduce insomnia and agitation in acute mania |
CCBs: benefit in bipolar | in lithium pts unable to tolerate AE |